{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "20409374",
  "DateCompleted": {
    "Year": "2010",
    "Month": "07",
    "Day": "30"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "10",
    "Day": "20"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.3201/eid1605.071606"
    ],
    "Journal": {
      "ISSN": "1080-6059",
      "JournalIssue": {
        "Volume": "16",
        "Issue": "5",
        "PubDate": {
          "Year": "2010",
          "Month": "May"
        }
      },
      "Title": "Emerging infectious diseases",
      "ISOAbbreviation": "Emerg Infect Dis"
    },
    "ArticleTitle": "Multihospital outbreak of Clostridium difficile infection, Cleveland, Ohio, USA.",
    "Pagination": {
      "StartPage": "827",
      "EndPage": "829",
      "MedlinePgn": "827-9"
    },
    "Abstract": {
      "AbstractText": [
        "To determine whether a multihospital Clostridium difficile outbreak was associated with epidemic strains and whether use of particular fluoroquinolones was associated with increased infection rates, we cultured feces from C. difficile-infected patients. Use of fluoroquionolones with enhanced antianaerobic activity was not associated with increased infection rates."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "University Hospitals of Cleveland, Cleveland, Ohio, USA."
          }
        ],
        "LastName": "Jump",
        "ForeName": "Robin L P",
        "Initials": "RL"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Riggs",
        "ForeName": "Michelle M",
        "Initials": "MM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Sethi",
        "ForeName": "Ajay K",
        "Initials": "AK"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Pultz",
        "ForeName": "Michael J",
        "Initials": "MJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Ellis-Reid",
        "ForeName": "Tracie",
        "Initials": "T"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Riebel",
        "ForeName": "William",
        "Initials": "W"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Gerding",
        "ForeName": "Dale N",
        "Initials": "DN"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Salata",
        "ForeName": "Robert A",
        "Initials": "RA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Donskey",
        "ForeName": "Curtis J",
        "Initials": "CJ"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, U.S. Gov't, Non-P.H.S."
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Emerg Infect Dis",
    "NlmUniqueID": "9508155",
    "ISSNLinking": "1080-6040"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Infective Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Aza Compounds"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Fluoroquinolones"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Quinolines"
    },
    {
      "RegistryNumber": "L4618BD7KJ",
      "NameOfSubstance": "Gatifloxacin"
    },
    {
      "RegistryNumber": "U188XYD42P",
      "NameOfSubstance": "Moxifloxacin"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Infective Agents"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Aza Compounds"
    },
    {
      "QualifierName": [
        "drug effects",
        "genetics",
        "isolation & purification"
      ],
      "DescriptorName": "Clostridioides difficile"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology",
        "microbiology"
      ],
      "DescriptorName": "Clostridium Infections"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology",
        "microbiology"
      ],
      "DescriptorName": "Cross Infection"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Disease Outbreaks"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Resistance, Bacterial"
    },
    {
      "QualifierName": [
        "microbiology"
      ],
      "DescriptorName": "Feces"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Fluoroquinolones"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Gatifloxacin"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Genes, Bacterial"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Hospitals"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Moxifloxacin"
    },
    {
      "QualifierName": [
        "epidemiology"
      ],
      "DescriptorName": "Ohio"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Quinolines"
    }
  ]
}